Geng Xiaocong, Liu Yueyang, Dreyer Tobias, Bronger Holger, Drecoll Enken, Magdolen Viktor, Dorn Julia
Department of Obstetrics and Gynecology, Technische Universität München Munich, Germany.
Institute of Pathology, Technische Universität München Munich, Germany.
Am J Cancer Res. 2018 Sep 1;8(9):1856-1864. eCollection 2018.
Several members of the KLK family have been proposed to modulate various tumor-relevant processes. Previously, we have shown that in advanced high-grade serous ovarian cancer tissue high KLK11 mRNA levels were significantly associated with prolonged overall and progression-free patients' survival. Furthermore, KLK11 mRNA expression positively correlated with KLK10 mRNA. In the present study, we examined the prognostic value for both KLK10 and KLK11 on the protein expression level by immunohistochemistry (IHC). A cohort encompassing 159 patient tumor samples afflicted with advanced high-grade (FIGO III/IV) serous ovarian cancer, present on tissue microarrays (TMA), was analyzed. For estimation of KLK10 and KLK11 immunoreactivity, an automated digital IHC image analysis algorithm was selected to quantify the antibody staining intensity in the tissues via an immunoreactive score (IRS). In line with the results obtained by mRNA analysis, KLK10 protein expression values were significantly and positively correlated with KLK11 protein expression values. In Kaplan-Meier analyses, both elevated KLK10, KLK11, and the combination of KLK10 and KLK11 protein levels were significantly linked with prolonged overall survival (OS). The addition of KLK10, KLK11 or the KLK10+KLK11 combination IRS to the base model in multivariate Cox analysis demonstrated that high KLK11 and KLK10+KLK11 protein expression levels, apart from clinical parameters, remained favorable independent predictive markers for OS. In conclusion, in the present study, we have validated the coordinate expression of KLK10 and KLK11 in advanced high-grade serous ovarian cancer. Furthermore, both increased KLK10 and KLK11 protein expression is associated with favorable prognosis in this major ovarian cancer subtype. The combined KLK10+KLK11 marker performed even stronger than KLK10 or KLK11 alone.
已有人提出KLK家族的几个成员可调节各种肿瘤相关过程。此前,我们已经表明,在晚期高级别浆液性卵巢癌组织中,KLK11 mRNA高水平与患者总生存期和无进展生存期的延长显著相关。此外,KLK11 mRNA表达与KLK10 mRNA呈正相关。在本研究中,我们通过免疫组织化学(IHC)检测了KLK10和KLK11在蛋白质表达水平上的预后价值。分析了组织微阵列(TMA)上包含159例患有晚期高级别(FIGO III/IV)浆液性卵巢癌患者肿瘤样本的队列。为了评估KLK10和KLK11的免疫反应性,选择了一种自动数字IHC图像分析算法,通过免疫反应评分(IRS)对组织中的抗体染色强度进行量化。与mRNA分析结果一致,KLK10蛋白表达值与KLK11蛋白表达值显著正相关。在Kaplan-Meier分析中,KLK10、KLK11水平升高以及KLK10和KLK11蛋白水平的组合均与总生存期(OS)延长显著相关。在多变量Cox分析中,将KLK10、KLK11或KLK10 + KLK11组合的IRS添加到基础模型中表明,除临床参数外,高KLK11和KLK10 + KLK11蛋白表达水平仍然是OS的良好独立预测标志物。总之,在本研究中,我们验证了KLK10和KLK11在晚期高级别浆液性卵巢癌中的协同表达。此外,在这种主要的卵巢癌亚型中,KLK10和KLK11蛋白表达增加均与良好的预后相关。KLK10 + KLK11联合标志物的表现甚至比单独的KLK10或KLK11更强。